Eli Lilly has announced that the addition of Gemzar to the current standard of care provided a statistically significant increase in progression-free survival at three years for women with locally advanced cervical cancer.
The phase III trial data conducted on 515 patients showed a significant increase in progression-free survival at three years for patients treated with the gemcitabine chemoradiation combination versus those treated only with chemoradiation.
Patients on the gemcitabine arm experienced significantly more grade 3/4 toxicities.
Eli Lilly vice-president of cancer research and global oncology platform leader Richard Gaynor said that "Lilly continues to look for ways to improve the survival of people living with cancer and fill unmet needs in difficult-to-treat cancers".
Results from this global, multicentre, open-label, randomised Phase III trial were presented at the 45th Annual Meeting of the American Society of Clinical Oncology.